Samsung Bioepis Launches Ustekinumab Biosimilar, Marking Its First Product Launch in Japan
Ustekinumab BS 45 mg Syringe for S.C. Injection「NIPRO」 is now available in Japan, after its listing under the National Health Insurance (NHI) Drug Price Standard
First Guests Arrive at Four Seasons Resort and Residences Red Sea at Shura Island from 20 May
RSG and Kingdom Holding Company bring first joint venture-developed resort at The Red Sea to market
